Metabolic reprogramming in osteoclasts.
Animals
Bone Remodeling
/ genetics
Bone Resorption
Bone and Bones
/ cytology
Cellular Reprogramming
Energy Metabolism
Glycolysis
Humans
Lipid Metabolism
Mitochondria
/ metabolism
Organelle Biogenesis
Osteoclasts
/ cytology
Oxidative Phosphorylation
Signal Transduction
TOR Serine-Threonine Kinases
/ metabolism
Metabolic reprogramming
Metabolism
Osteoclasts
Journal
Seminars in immunopathology
ISSN: 1863-2300
Titre abrégé: Semin Immunopathol
Pays: Germany
ID NLM: 101308769
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
08
04
2019
accepted:
05
09
2019
pubmed:
26
9
2019
medline:
30
4
2020
entrez:
26
9
2019
Statut:
ppublish
Résumé
Osteoclasts are bone-resorbing cells that play an essential role in the remodeling of the bone. Defects in osteoclasts thus result in unbalanced bone remodeling, leading to numerous pathological conditions such as osteoporosis, bone metastasis, and inflammatory bone erosion. Metabolism is any process a cell utilizes to meet its energetic demand for biological functions. Along with signaling pathways and osteoclast-specific gene expression programs, osteoclast differentiation activates metabolic programs. The energy generated from metabolic reprogramming in osteoclasts not only supports the phenotypic changes from mononuclear precursor cells to multinuclear osteoclasts, but also facilitates bone resorption, a major function of terminally differentiated, mature osteoclasts. While oxidative phosphorylation is studied as a major metabolic pathway that fulfills the energy demands of osteoclasts, all metabolic pathways are closely interconnected. Therefore, it remains important to understand the various aspects of osteoclast metabolism, including the roles and effects of glycolysis, glutaminolysis, fatty acid synthesis, and fatty acid oxidation. Targeting the pathways associated with metabolic reprogramming has shown beneficial effects on pathological conditions. As a result, it is clear that a deeper understanding of metabolic regulation in osteoclasts will offer broader translational potential for the treatment of human bone disorders.
Identifiants
pubmed: 31552471
doi: 10.1007/s00281-019-00757-0
pii: 10.1007/s00281-019-00757-0
pmc: PMC7671717
mid: NIHMS1643140
doi:
Substances chimiques
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-572Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR069562
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073156
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01AR069562
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01AR73156
Pays : United States
Références
Commun Biol. 2018 Apr 5;1:29
pubmed: 30271915
Nat Genet. 2000 May;25(1):87-90
pubmed: 10802663
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16568-73
pubmed: 24023068
Clin Transl Immunology. 2016 Apr 22;5(4):e73
pubmed: 27195116
J Lipid Res. 2010 May;51(5):892-9
pubmed: 20388920
J Biol Chem. 2012 Jun 1;287(23):19229-41
pubmed: 22500026
Nat Rev Cancer. 2008 Sep;8(9):705-13
pubmed: 19143055
Nat Commun. 2018 Jan 4;9(1):55
pubmed: 29302038
FASEB J. 2010 Dec;24(12):4648-59
pubmed: 20667978
J Biochem. 2016 Jan;159(1):1-8
pubmed: 26538571
Immunity. 2014 Oct 16;41(4):518-28
pubmed: 25367569
Nat Cell Biol. 2018 Jul;20(7):745-754
pubmed: 29950572
Cell Metab. 2016 Mar 8;23(3):479-91
pubmed: 26777690
J Biol Chem. 2012 Nov 2;287(45):37808-23
pubmed: 22988253
J Biophys Biochem Cytol. 1961 Dec 1;11(3):627-49
pubmed: 19866598
Front Cell Dev Biol. 2017 May 18;5:54
pubmed: 28573133
Trends Endocrinol Metab. 2010 Dec;21(12):722-8
pubmed: 20863714
Nat Cell Biol. 2018 Jul;20(7):755-765
pubmed: 29950571
Trends Endocrinol Metab. 2012 Nov;23(11):582-90
pubmed: 22705116
PLoS One. 2016 Apr 14;11(4):e0153886
pubmed: 27077737
Annu Rev Cell Dev Biol. 2011;27:441-64
pubmed: 21985671
Cell Metab. 2010 Jun 9;11(6):503-16
pubmed: 20519122
Nat Genet. 2002 Jul;31(3):289-94
pubmed: 12068295
J Bone Miner Res. 2015 Dec;30(12):2287-99
pubmed: 26094846
Nat Med. 2015 Mar;21(3):281-7
pubmed: 25706873
J Bone Miner Metab. 2010 Jul;28(4):410-7
pubmed: 20127130
Immunity. 2017 Jul 18;47(1):66-79.e5
pubmed: 28723554
Bone Res. 2018 Jan 30;6:1
pubmed: 29423330
J Pathol. 2009 Jun;218(2):256-64
pubmed: 19291710
JCI Insight. 2017 Aug 17;2(16):
pubmed: 28814665
Annu Rev Biochem. 2015;84:865-94
pubmed: 25747398
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Science. 1999 Dec 3;286(5446):1946-9
pubmed: 10583956
Cell Death Differ. 2004 Jul;11 Suppl 1:S108-18
pubmed: 15017384
Nat Rev Genet. 2003 Aug;4(8):638-49
pubmed: 12897775
Cell Death Differ. 2003 Oct;10(10):1165-77
pubmed: 14502240
J Bone Miner Res. 2014;29(5):1183-95
pubmed: 24272998
J Bone Miner Res. 2013 Nov;28(11):2392-9
pubmed: 23661628
Clin Sci (Lond). 2007 Jun;112(11):567-75
pubmed: 17241109
J Bone Miner Res. 2013 Apr;28(4):711-22
pubmed: 23436579
Stem Cell Reports. 2017 Jun 6;8(6):1600-1616
pubmed: 28479301
Cell Rep. 2015 Jun 16;11(10):1625-37
pubmed: 26051940
Cell Metab. 2008 Dec;8(6):512-21
pubmed: 19041766
Nat Rev Mol Cell Biol. 2012 Mar 07;13(4):270-6
pubmed: 22395772
Bone. 1998 Aug;23(2):135-40
pubmed: 9701472
PLoS One. 2015 Apr 13;10(4):e0125145
pubmed: 25867515
Am J Physiol Cell Physiol. 2007 May;292(5):C1599-605
pubmed: 17182725
Bone. 2018 Oct;115:2-7
pubmed: 28843700
Curr Osteoporos Rep. 2013 Sep;11(3):203-12
pubmed: 23857286
Cell Metab. 2014 Sep 2;20(3):483-98
pubmed: 25130399
J Clin Invest. 2017 Jun 30;127(7):2555-2568
pubmed: 28530645
J Biol Chem. 2017 Jan 6;292(1):196-204
pubmed: 27879318
J Pathol. 2013 Apr;229(5):755-64
pubmed: 23303559
Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):e6-10
pubmed: 14670933
Int J Biochem Cell Biol. 2016 Oct;79:168-180
pubmed: 27590854
Am J Physiol. 1999 Jun;276(6):F837-46
pubmed: 10362772
Nat Med. 2009 Mar;15(3):259-66
pubmed: 19252502
J Clin Invest. 2016 Jun 1;126(6):2049-63
pubmed: 27111232
J Bone Miner Metab. 2010 Sep;28(5):510-9
pubmed: 20300790
J Bone Miner Res. 2003 Jul;18(7):1206-16
pubmed: 12854830